Pharmacovigilance services

Product Description

System set-up (QPPV, PSMF, SOP and QMS, SDEAs), Database and case management, Literature screening (global & local), Safety profile monitoring & aggregate reporting (PSUR, RMP, Signal detection), XEVMPD and Administrative support, Local PV Network

Pharmathen Global BV

  • NL
  • 2015
    On CPhI since

Pharmathen Global BV

  • NL
  • 2015
    On CPhI since

More Products from Pharmathen Global BV

  • Sevelamer Carbonate Chewable

    Product Sevelamer Carbonate Chewable

    Pharmaceutical form: fast disintegrating chewable tablets. Therapeutic category: Control of serum phosphorous in patients with chronic kidney disease.
    Strengths: 800mg.
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Bimatoprost

    Product Bimatoprost

    Pharmaceutical form: eye drops solution. Therapeutic indication: reduction of elevated intraocular pressure in open angle glaucoma ocular hypertension.
    Strengths: 0.1mg/ml, 0.3mg/ml
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Aripiprazole LAI

    Product Aripiprazole LAI

    Pharmaceutical form: Long acting injectable. Therapeutic category: Treatment of schizophrenia.
    Strengths: 300mg/vial & 400mg/vial ,300mg/syringe & 400mg/syringe.
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Alendronate + Cholecalciferol

    Product Alendronate + Cholecalciferol

    Pharmaceutical form: Tablets Therapeutic category: Postmenopausal osteoporosis.
    Strengths: 70mg/2800IU & 70mg/5600IU
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Aprepitant

    Product Aprepitant

    Pharmaceutical form: Hard Capsules. Therapeutic category: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
    Strengths: 40mg, 80mg, 125mg, 165mg (Not available in the US market).
    Contact us for more information.  
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Aripiprazole

    Product Aripiprazole

    Pharmaceutical form: orodispersible tablets/ fc. tablets; Therapeutic category: Schizophrenia, manic episode treatment.
    Strengths orodispersible tablets: 10mg, 15mg, 30mg.
    Strengths tablets: 5mg, 10mg, 15mg, 30mg.
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Aripiprazole Lauroxil LAI

    Product Aripiprazole Lauroxil LAI

    Pharmaceutical form: Long acting injectable. Therapeutic category: Treatment of Schizophrenia in adult patients stabilized with oral aripiprazole.
    Strengths: 441mg/syringe, 662mg/syringe, 882mg/syringe,1064mg/syringe
    Contact us for more information.

    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Atomoxetine

    Product Atomoxetine

    Pharmaceutical form: Hard capsules. Therapeutic category: Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
    Strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg,100mg.
    Contact us for more information.

    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Atorvastatin

    Product Atorvastatin

    Pharmaceutical form: f.c. tablets. Therapeutic category: Hypercholesterolemia treatment, cardiovascular disease prevention.
    Strengths: 10mg, 20mg, 40mg, 80mg.
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Bimatoprost Preservative free

    Product Bimatoprost Preservative free

    Pharmaceutical form: eye drops solution multidose container. Therapeutic category: reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension.
    Strengths: 0.3mg/ml, 0.1mg/ml (US market only).
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Brimonidine Preservative free

    Product Brimonidine Preservative free

    Pharmaceutical form: eye drops solution, multi dose container. Therapeutic category: Reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
    Strengths: 2mg/ml
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.

  • Brimonidine Timolol Preservative free

    Product Brimonidine Timolol Preservative free

    Pharmaceutical form: eye drops solution, multi dose container. Therapeutic category: Reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.
    Strengths: 2mg/ml, 5mg/ml.
    Contact us for more information.
    Products which are subject to patent protection are currently not offered or made available in Italy or in countries wherein patents & SPCs are in force. No orders or deliveries, prior to the expiry date of valid patents & SPCs are possible.


Pharmathen Global BV resources

  • News MedPharm is people’s choice after inaugural CPhI Innovation in Response to COVID-19 Pitch Session

    MedPharm was the people’s choice for the inaugural CPhI Innovation in Response to COVID-19 award after an absorbing Pitch Session, sponsored by Pharmathen, in which invited shortlisted finalists each pitched their entry to the event’s virtual audience.
  • Brochure Services Catalogue 2020

    Our 50 years’ experience allows us to offer professional services like third party audits and GMP services, advice on regulatory affairs, drug safety & pharmacovigilance services, scientific operations services, IP services and corporate quality management.
  • Brochure USA Product Catalogue 2020

    At Pharmathen our main priority is to develop innovative products, so as to improve patient compliance and offer a better quality of life. Our products cover a wide range of therapeutic areas and are developed using our in-house technologies. Backed up with reliable and quality supply of products manufactured in our 2 facilities in Greece (Pallini, Attika and Sapes, Rodopi) or through our network of contract partners.
  • Brochure API Product Catalogue 2020

    At Pharmathen our main priority is to develop innovative products, so as to improve patient compliance and offer a better quality of life. Our products cover a wide range of therapeutic areas and are developed using our in-house technologies. Backed up with reliable and quality supply of products manufactured in our 2 facilities in Greece (Pallini, Attika and Sapes, Rodopi) or through our network of contract partners.
  • Brochure Global Product Catalogue 2020

    At Pharmathen our main priority is to develop innovative products, so as to improve patient compliance and offer a better quality of life. Our products cover a wide range of therapeutic areas and are developed using our in-house technologies. Backed up with reliable and quality supply of products manufactured in our 2 facilities in Greece (Pallini, Attika and Sapes, Rodopi) or through our network of contract partners.
  • Video Pharmathen's new LAI unit

    Take a sneak peek of our new LAI unit in Sapes (Rodopi, Greece).
  • Video CPhI Pharma Awards – Innovation in response to COVID-19.

    2020 has been an extraordinary year with extraordinary challenges. As champions of innovation in Pharma, CPhI has introduced a new category to the 17th edition of the CPhI Pharma Awards – Innovation in response to COVID-19. This category is designed to recognise innovation in technologies, products, processes, and services to combat the impact of COVID-19 on individuals, patients, healthcare professionals and communities. Including the development and manufacture of potential vaccines, drug products and medical equipment and the introduction of services, solutions and resources to provide support to those effected by the pandemic. Finalists in this category are as follows: Aptar Pharma, ActivShield™ by Aptar CSP Technologies Beximco Pharmaceuticals Catalent Crystec Pharma, mSAS® Technology Dr Reddy’s Farmalabor srl Ridgeback Biotherapeutics, MK-4482 – in collaboration with Merck MedPharm Join us for this 'Innovation Pitch Session', sponsored by Pharmathen, in which we invite shortlisted candidates to deliver their product pitches to you, the CPhI Audience. The Jury have cast their vote, now it's your turn! Winners will be announced at the CPhI Pharma Awards on Tuesday 13th October.

Recommended products